Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML

Overview of attention for article published in Clinical Proteomics, July 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 15 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 20,259 followers.

This work will continue the study of drug sensitivity in AML https://t.co/3ixWTR5i3Z. We have many more papers in the pipeline and datasets that are still unmined.

12 Jul 2023

Reply Repost Favourite

What up @sargoshoe! Congratulations!

20 Sep 2022

Reply Repost Favourite

RT @NCIgenomics: #CPTAC study harnesses #proteogenomic info to reveal insights into drug sensitivity in FLT3 and Ras/MEK pathways in Beat…

20 Sep 2022

Reply Repost Favourite

#CPTAC study harnesses #proteogenomic info to reveal insights into drug sensitivity in FLT3 and Ras/MEK pathways in Beat AML cohort https://t.co/gO3pJv3ujT https://t.co/jJQfbGdVGd

20 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.